Kezar Life Sciences Inc. (KZR)
6.16
0.27 (4.58%)
At close: Mar 24, 2025, 3:59 PM
6.16
-0.03%
After-hours: Mar 24, 2025, 07:56 PM EDT
4.58% (1D)
| Bid | 6.08 |
| Market Cap | 44.97M |
| Revenue (ttm) | -543.08K |
| Net Income (ttm) | -9.58M |
| EPS (ttm) | -13.12 |
| PE Ratio (ttm) | -0.47 |
| Forward PE | -0.7 |
| Analyst | Hold |
| Ask | 6.24 |
| Volume | 104,804 |
| Avg. Volume (20D) | 29,415 |
| Open | 6.20 |
| Previous Close | 5.89 |
| Day's Range | 6.00 - 6.37 |
| 52-Week Range | 5.20 - 10.10 |
| Beta | 0.49 |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 58
Stock Exchange NASDAQ
Ticker Symbol KZR
Analyst Forecast
According to 2 analyst ratings, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 46.10% from the latest price.
Stock Forecasts5 months ago
+42.1%
Kezar Life Sciences shares are trading higher afte...
Unlock content with
Pro Subscription
